TenNor Therapeutics (Suzhou) Ltd is a China-based company primarily engaged in the discovery and development of innovative drug products. The Company focuses on the fields of bacterial infections and bacterial metabolism diseases. The Company's products include Rifasutenizol (TNP-2198), a novel molecular entity candidate for the treatment of Helicobacter pylori, Rifaquizinone (TNP-2092) injection, a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections and TNP-2092 oral, multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism

© Copyright 1996-2026 irasia.com Ltd. All rights reserved.

DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website. TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website.